Letrozole Acdima is a medication used to treat specific categories of conditions, primarily in postmenopausal women. Its therapeutic function generally supports systemic management and symptomatic relief.

What Letrozole Acdima Treats: Main Uses and Benefits

This medication is applied in managing conditions characterized by periods of heightened symptoms, relevant for both early-stage disease, often following initial treatments, and for advanced or metastatic presentations. This includes applications for both advanced and early stages of hormone-dependent breast cancer.

The application of this medication is used for managing the condition, which may assist with symptom stabilization. It is commonly used across domains where additional symptomatic support is needed, such as in chronic settings, and is applied during phases of increased distress or discomfort.

“This supports the patient during difficult episodes by easing distress and helps maintain a sense of stability when symptoms are more noticeable.”

In situations where patients experience discomfort linked to organ-specific functional stress, it is applied in scenarios where additional management of discomfort is required, such as symptoms related to physical discomfort. This contributes to improved comfort during periods of heightened symptoms, and may assist with maintaining functional stability.

---

Quick Fact: Relief for Symptoms Related to Physical Discomfort

Letrozole Acdima’s eligibility is strictly defined by regulatory documents, primarily allowing use only in postmenopausal women whose endocrine status has been confirmed. No dose adjustment is generally required for adult or elderly patients based on age alone.

---

Contraindicated Populations

Use is contraindicated (absolutely prohibited) in several populations: women who are pregnant or breastfeeding; women of premenopausal endocrine status; and any patient with a known hypersensitivity to letrozole or its excipients.

---

Eligibility Restrictions

Official labeling requires specific considerations for certain health conditions:

• Children and Adolescents: Use is not recommended, as safety and efficacy have not been established in patients up to 17 years old.
• Severe Hepatic Impairment: Patients with severe liver dysfunction (Child-Pugh C) should be kept under close supervision.
• Severe Renal Impairment: Insufficient data are available for patients with very low creatinine clearance ( CrCl < 10 mL/min), requiring careful consideration before administration.
• Metabolic Conditions: The medicine is not recommended for patients with specific rare hereditary problems like galactose intolerance due to the presence of lactose.

Interactions with other medicines and products

Regulatory documents define specific interaction patterns for Letrozole, categorized by pharmacological mechanism and metabolic pathway. The most critical restriction is the formal prohibition of co-administration with oestrogens (e.g., Estrogen-Containing Therapies) and other anti-oestrogens like Tamoxifen, as these substances are documented to diminish the intended pharmacological action.

---

Pharmacokinetic Interactions

Letrozole's metabolism is primarily mediated by the liver enzymes CYP3A4 and CYP2A6. Interactions affecting these pathways modify Letrozole exposure.

• Increased Exposure: Strong CYP3A4 inhibitors (such as Ketoconazole or Itraconazole) may decrease metabolism, potentially leading to increased plasma concentrations of Letrozole.
• Decreased Exposure: Co-administration with CYP3A4 inducers (such as Rifampicin, Carbamazepine, or the herbal product St. John's Wort) may increase metabolism, potentially leading to decreased plasma concentrations (reduced exposure).

Letrozole itself can affect other medicines by acting as a moderate inhibitor of CYP2C19 in vitro. Regulatory caution is indicated for co-administration with medicines that have a narrow therapeutic index and whose elimination depends mainly on CYP2C19 (e.g., Phenytoin, Clopidogrel).

---

Population and Other Product Notes

• Severe Hepatic Impairment: In patients with severe hepatic impairment (Child-Pugh C), systemic exposure and the terminal half-life of Letrozole are documented to be approximately doubled.
• Food/Non-interactions: Letrozole absorption is not affected by food. Clinical studies have shown no clinically significant pharmacokinetic interaction with Warfarin or Cimetidine.

Selective Aromatase Enzyme Inhibition

Letrozole is classified as a non-steroidal Aromatase Inhibitor. Its primary mechanistic domain is the direct, competitive, and reversible inhibition of the Aromatase enzyme (CYP19A1). The molecule works by binding to the heme iron atom in the enzyme's active site, thereby blocking the enzyme's ability to function. This molecular interference prevents the final step of the estrogen biosynthesis pathway.

---

⬇️ Near-Complete Systemic Estrogen Suppression

This enzyme blockade results in a major pathway effect: the near-complete suppression of circulating estrogens, specifically estradiol ( E2) and estrone ( E1). Since estrogens are largely synthesized in peripheral tissues (like fat and muscle) via this enzyme, eliminating its function causes systemic estrogen deprivation. The mechanism exhibits high selectivity, ensuring it does not significantly affect the biosynthesis of essential adrenal hormones, a mechanism characteristic of non-steroidal Aromatase Inhibitors.

---

Anti-Proliferative Physiological Consequence

The resulting physiological consequence stems directly from the estrogen-deprived state. By eliminating estrogen, which acts as a hormonal growth factor, the drug removes the essential proliferative stimulus for estrogen-dependent cells. This mechanistic cascade, from molecular block to systemic hormonal reduction, results in a physiological adjustment that reduces the hormonal signaling stimulus for cell proliferation.

The administration of Letrozole Acdima is governed by specific instructions, which define its proper use as a standardized, long-term oral therapy.

Official Administration Guidelines

The standard regimen for Letrozole is a 2.5 mg tablet taken once daily. This single daily dose is the protocol across all approved uses, and the tablet is taken at the same time each day for consistency. The oral tablet should be swallowed whole and may be taken without regard to meals, as consumption of food does not significantly alter the drug's absorption.

Procedural Aspect	Official Requirement
Dose	2.5 mg once daily.
Route	Oral (by mouth).
Food Timing	Without regard to meals.
Intake Method	Swallowed whole (do not crush).

---

Duration and Special Use Constraints

The length of treatment with Letrozole is defined by the specific clinical context. For long-term use in the adjuvant setting, the medication is typically administered for a duration of five years. For advanced or metastatic presentations, administration generally continues until documented disease progression is observed.

Specialized instructions exist for managing specific patient populations. Patients diagnosed with severe hepatic impairment (Child-Pugh C) are directed to modify the standard regimen to 2.5 mg administered every other day. However, no dose adjustment is required for older adults or for patients with mild to moderate kidney impairment.

---

Handling Missed Doses

If a daily dose is missed, standard instructions are to take the dose as soon as it is remembered. However, if the time is close to the next scheduled administration, the missed dose should be skipped entirely. Patients are advised not to double doses to compensate for a forgotten one.

Research evidence / Overview of studies for Letrozole Acdima

Letrozole Acdima was evaluated extensively in large-scale clinical research, primarily focusing on postmenopausal women with hormone receptor-positive breast cancer. The information below summarizes the types of studies conducted and the outcomes they monitored, using findings from the major clinical research programs without providing treatment recommendations.

---

Evidence for Initial Adjuvant Treatment of Early Disease

The research context for this medicine's use as an initial therapy following surgery involves large, randomized trials where it was studied against other endocrine agents. Researchers monitored outcomes primarily related to the time until disease relapse (Disease-Free Survival or DFS). Findings describe group patterns related to DFS, which was monitored and measured over observation periods of several years.

What remains uncertain is the full characterization of long-term effects, especially for overall survival, as data for this outcome are still emerging. Comparative evidence is still developing regarding the long-term strategy of using this medicine alone versus using it sequentially with other endocrine agents.

---

Evidence for Extended Adjuvant Treatment of Early Disease

The extended use of this medicine was evaluated in large randomized trials that compared it against a placebo (an inactive substance) for a planned period of five years. These studies involved postmenopausal women who were disease-free after already completing a prior course of endocrine therapy. Researchers examined primary outcomes related to preventing the recurrence of cancer and preventing new cancer in the opposite breast.

Findings describe patterns observed in the studies related to Disease-Free Survival when comparing the group receiving the medicine to the group receiving placebo. However, long-term findings related to Overall Survival (OS) were affected because many patients originally assigned to the placebo group were given the option to switch to this medicine after initial results were released.

---

Evidence for Advanced and Metastatic Disease

Research examined the use of this medicine as an initial hormonal treatment for postmenopausal women whose disease was locally advanced or had spread to distant sites (metastatic). Primary outcomes monitored included the duration until the disease worsened (Time to Progression or TTP) and the rate at which tumors shrank (Objective Response Rate). Findings describe patterns observed in these studies, where time-to-progression measurements were observed in relation to the comparison treatment.

More recent research has also explored this medicine in combination with newer targeted therapies, and research on this medicine used alone is placed within the broader evidence landscape. Data are still emerging for overall survival when used as a single agent in this setting, as long-term effects are not fully established.

Key Studies & References

1. Study Details | NCT00004205 | Letrozole or Tamoxifen in Treating Postmenopausal Women With Breast Cancer (BIG 1-98)
2. Femara Art 30 - CHMP Opinion - European Commission (Neoadjuvant and Adjuvant Treatment Summaries)

Common questions about Letrozole Acdima (FAQ)

---

Q: Is Letrozole Acdima the same as other aromatase inhibitors?

Regulatory documents classify the active ingredient, Letrozole, as a non-steroidal third-generation aromatase inhibitor. This is a specific classification used to distinguish its chemical structure and way of working from earlier types of anti-estrogenic medicines.

Q: Is Letrozole Acdima safe to take long-term?

Official information documents that extended treatment, such as the typical five-year duration, is associated with the long-term risk of conditions like osteoporosis and bone fracture. Regulatory agencies document that monitoring for these specific risks may be considered during long-term use.

Q: Why do official documents describe Letrozole Acdima as being for postmenopausal women?

The drug's primary function is to decrease the production of estrogen in the body. Because of this powerful mechanism, eligibility is strictly defined in regulatory documents for postmenopausal women.

Q: What is the difference between Letrozole Acdima and Tamoxifen?

Letrozole is an aromatase inhibitor that works by stopping estrogen production. Tamoxifen is a different type of hormone therapy known as a Selective Estrogen Receptor Modulator (SERM). Regulatory documents describe that co-administration of the two medicines is prohibited.

Q: Is Letrozole Acdima a chemotherapy drug?

The medicine is classified as an antineoplastic agent that works by performing endocrine therapy, also known as hormone treatment. This is distinct from traditional cytotoxic chemotherapy, as it works by inhibiting the production of estrogen.

Q: Why is the drug called Letrozole Acdima?

Letrozole is the name of the active ingredient in the medicine. The addition of Acdima is associated with the Arab Company for Pharmaceutical Industries and Medical Supplies, indicating the specific manufacturer or brand.

Q: Does taking Letrozole Acdima require regular blood tests?

Regulatory guidance advises patients to consider the regular monitoring of Bone Mineral Density (BMD) and serum cholesterol during treatment. Monitoring of these parameters generally involves laboratory testing or scans.

Q: What is the main reason doctors prescribe Letrozole Acdima?

According to official product information, this medicine is approved to treat hormone receptor-positive breast cancer in women who have experienced menopause. This includes treatment for early-stage, extended adjuvant, and advanced forms of the disease.

Q: Does Letrozole Acdima cause weight gain?

Regulatory documents list weight gain as a possible adverse reaction. It is also noted that weight loss is listed as another possible side effect.

Q: How long does it typically take for Letrozole Acdima to start working?

Official patient information states that the medicine begins to reduce estrogen levels immediately upon starting treatment. However, official information indicates that it may take several weeks or months to observe the full physiological effects of the medicine.

Q: Can men take Letrozole Acdima?

The medicine’s official approved use is strictly defined in the regulatory documents for postmenopausal women. Safety and efficacy for the medicine's primary indication have not been established in males within the prescribing information.

Q: Can Letrozole Acdima be taken with blood pressure medication?

Specific studies on interactions with common blood pressure medications are not detailed in official regulatory text. Official caution documents that patients are encouraged to provide their healthcare team with a complete list of all medicines they are taking due to potential interaction concerns.

Q: Does alcohol interact negatively with Letrozole Acdima?

Official patient warnings note that alcohol may increase side effects such as tiredness or dizziness, which are already possible with this medicine. These effects could be intensified when alcohol is consumed.

Q: Can I take vitamins or supplements while on Letrozole Acdima?

Official caution documents that patients are encouraged to provide their doctor with a complete list of all vitamins, supplements, and herbal remedies they are taking. This is because there is often not enough safety information on most supplements when taken alongside this medicine.

Q: How long do the side effects of Letrozole Acdima usually last?

Official patient information notes that common side effects, especially those related to the decrease in estrogen, usually occur during the first few weeks of treatment. These symptoms have been noted to gradually improve as the body adjusts to the medicine.

Q: Does Letrozole Acdima affect mood or cause depression?

Depression is listed in regulatory documents as a common side effect. Furthermore, anxiety and irritability are also noted as possible adverse reactions reported in studies.

Q: Does Letrozole Acdima cause hair loss?

Hair loss or hair thinning is listed in official patient information as a possible adverse reaction. This is consistent with other effects related to the decrease in circulating estrogen.

Q: Can I drive while taking Letrozole Acdima?

Regulatory patient warnings caution against driving or operating machinery if the patient experiences side effects such as fatigue, dizziness, or drowsiness. Patients are cautioned to understand their own reaction to the medicine before operating a vehicle.

Q: Will taking Letrozole Acdima change my metabolism?

Official documents describe the medicine's own metabolism by liver enzymes, specifically CYP2A6 and CYP3A4. It is also associated with metabolic side effects, such as a high cholesterol level (hypercholesterolaemia).

Q: Are generic versions of Letrozole Acdima available?

Regulatory sources, such as the FDA, confirm that multiple generic versions of the active ingredient, letrozole, have been approved for use.

Q: What happens when you stop taking Letrozole Acdima?

Official patient information states that sudden discontinuation of the medicine is not recommended and should be discussed with a specialist. It is important to discuss alternatives for treatment or discontinuation beforehand.

Q: What are the signs of a serious allergic reaction to Letrozole Acdima?

Official patient information warns to look for signs like a rash, hives, or difficulty breathing. Other serious signs include swelling of the mouth, face, lips, tongue, or throat.

Q: Is the effect of Letrozole Acdima permanent?

The drug is classified as a competitive and reversible inhibitor of the aromatase enzyme, which is the enzyme it blocks. This classification indicates that the drug's effect on estrogen suppression is temporary and generally ceases after administration is stopped.

Q: Can Letrozole Acdima affect sleep?

Insomnia (trouble sleeping) is listed in regulatory documents as a possible adverse reaction. Conversely, somnolence (drowsiness or sleepiness) is also listed as a possible side effect.

Official Storage Requirements

Letrozole tablets must be stored at controlled room temperature, typically between 20 C and 25 C (68 F and 77 F). The medication must be kept in its original, tightly closed container and protected from excess heat, moisture, and direct light; it must not be frozen. To maintain stability, the product should be used by the expiration date printed on the packaging.

Child Safety and Handling

It is an official requirement to keep Letrozole out of the sight and reach of children and pets, ideally in a secured location. The container should be closed securely after each use.

Disposal Instructions

Do not flush Letrozole down the toilet or pour it into a drain. Unused or expired medication should be disposed of primarily through a drug take-back program or an authorized collector. If a take-back option is unavailable, the medication can be mixed with an undesirable substance (such as dirt or coffee grounds) in a sealed bag before being discarded with household trash.